Drug intelligence / Profile preview

CTX-8573

Development stage: Discontinued
Lead developer: Compass Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CTX-8573 is a first-in-class, common light chain-based bispecific antibody targeting B-cell maturation antigen (BCMA) and NKp30. It is designed to selectively activate natural killer cells to destroy BCMA-expressing tumor cells in hematological malignancies such as multiple myeloma. Developed by Compass Therapeutics, it is a potent stimulant of innate immunity through antibody-dependent cellular cytotoxicity (ADCC) and NK cell activation.

Targets

FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)BCMA (B-cell maturation antigen)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))

Beyond the preview

Go deeper on CTX-8573.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX-8573.

Explore the full profile